Estimation of serum pyruvic acid levels in oral squamous cell carcinoma.
Glycolysis
oral squamous cell carcinoma
pyruvic acid
Journal
Journal of oral and maxillofacial pathology : JOMFP
ISSN: 0973-029X
Titre abrégé: J Oral Maxillofac Pathol
Pays: India
ID NLM: 101227995
Informations de publication
Date de publication:
Historique:
received:
17
08
2019
revised:
25
09
2020
accepted:
03
11
2020
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
ppublish
Résumé
Cancer cells generally exhibit increased glycolysis for adenosine triphosphate generation (the Warburg effect) due to mitochondrial respiration injury and hypoxia, which are frequently associated with resistance to therapeutic agents. Pyruvic acid is produced as an end product of glycolysis along with lactic acid. At room temperature, lactic acid converts into pyruvic acid as it is chemically unstable. To evaluate the serum pyruvic acid levels in patients with oral squamous cell carcinoma (OSCC). Thirty clinically and histopathologically confirmed cases of OSCC were included in the study. The cases were staged clinically (tumor-node-metastasis staging) and graded histopathologically (modified Broder's classification). A control group of 30 age-matched individuals with no systemic diseases were selected and the serum levels of pyruvic acid were measured and the absorbance was read using a spectrophotometer at a wavelength of 540 nm. The results were evaluated statistically and discussed. Pair-wise comparison of clinical stages and histological grades of OSCC was done using Tukey's multiple post hoc procedure. The increase in mean serum pyruvic acid levels between any two groups and grades was found to be statistically significant respectively ( Serum pyruvic acid levels gradually increased from individuals without OSCC to individuals with OSCC. Higher levels of serum pyruvic acid were seen with increasing clinical stage and the mean serum pyruvic acid levels were also found to be significantly increasing with advancing histopathological grades of OSCC.
Identifiants
pubmed: 33967514
doi: 10.4103/jomfp.JOMFP_246_19
pii: JOMFP-24-585b
pmc: PMC8083397
doi:
Types de publication
Journal Article
Langues
eng
Pagination
585Informations de copyright
Copyright: © 2021 Journal of Oral and Maxillofacial Pathology.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
PLoS One. 2014 Jun 09;9(6):e98581
pubmed: 24911788
Pac Health Dialog. 2003 Mar;10(1):76-8
pubmed: 16276948
J Int Soc Prev Community Dent. 2015 Nov-Dec;5(6):446-50
pubmed: 26759796
J Clin Pathol. 1962 Nov;15:579-84
pubmed: 13928482
J Biol Chem. 2003 Apr 25;278(17):15333-40
pubmed: 12566445
Cancer Res. 2006 Sep 15;66(18):8927-30
pubmed: 16982728
Asian Pac J Cancer Prev. 2014;15(20):8887-91
pubmed: 25374224
Biochem J. 2012 Jun 15;444(3):561-71
pubmed: 22458763
Int J Cell Biol. 2012;2012:843505
pubmed: 22778743
J Oral Maxillofac Pathol. 2014 Sep-Dec;18(3):372-8
pubmed: 25948991
Cancer Invest. 2002;20(4):557-69
pubmed: 12094550
Biochem J. 2009 Jan 1;417(1):379-89
pubmed: 18789002
Oral Oncol. 2010 Apr;46(4):226-31
pubmed: 20138569
Toxicol Res. 2014 Sep;30(3):193-8
pubmed: 25343013
Cell. 2008 Sep 5;134(5):703-7
pubmed: 18775299
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jun;115(6):764-71
pubmed: 23570662
Annu Rev Cell Dev Biol. 2011;27:441-64
pubmed: 21985671
Cancer. 1981 Mar 1;47(5 Suppl):1151-3
pubmed: 6165453
Aging Cell. 2014 Jun;13(3):519-28
pubmed: 24612481
J Clin Exp Dent. 2015 Oct 01;7(4):e462-5
pubmed: 26535090
Cancers (Basel). 2010 Mar 22;2(1):190-208
pubmed: 24281040
Br J Cancer. 2000 Dec;83(12):1696-701
pubmed: 11104568
J Oral Maxillofac Pathol. 2016 Jan-Apr;20(1):102-5
pubmed: 27194870
Cancer Res. 2005 Jan 15;65(2):613-21
pubmed: 15695406
Indian J Cancer. 2014 July-September;51(3):214-218
pubmed: 25494107
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683